Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

References for PMC Articles for PubMed (Select 21558394)

1.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

2.

Response definition criteria for ELISPOT assays revisited.

Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15.

3.

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.

Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Löwik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH.

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9. doi: 10.1073/pnas.1006500107. Epub 2010 Jun 14.

4.

An integrative paradigm to impart quality to correlative science.

Kalos M.

J Transl Med. 2010 Mar 16;8:26. doi: 10.1186/1479-5876-8-26. Review.

5.

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR; Biomarkers Task Force of the NCI Investigational Drug Steering Committee.

Clin Cancer Res. 2010 Mar 15;16(6):1745-55. doi: 10.1158/1078-0432.CCR-09-2167. Epub 2010 Mar 9.

6.

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team; VRC 010 Study Team.

PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015.

7.

Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2010 Apr;59(4):619-27. doi: 10.1007/s00262-009-0814-4. Epub 2010 Jan 6.

8.

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.

Dangoor A, Lorigan P, Keilholz U, Schadendorf D, Harris A, Ottensmeier C, Smyth J, Hoffmann K, Anderson R, Cripps M, Schneider J, Hawkins R.

Cancer Immunol Immunother. 2010 Jun;59(6):863-73. doi: 10.1007/s00262-009-0811-7. Epub 2009 Dec 31.

PMID:
20043222
9.

Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.

Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH, Dockrell HM, Mascart F.

PLoS One. 2009 Nov 24;4(11):e7972. doi: 10.1371/journal.pone.0007972.

10.

Data File Standard for Flow Cytometry, version FCS 3.1.

Spidlen J, Moore W, Parks D, Goldberg M, Bray C, Bierre P, Gorombey P, Hyun B, Hubbard M, Lange S, Lefebvre R, Leif R, Novo D, Ostruszka L, Treister A, Wood J, Murphy RF, Roederer M, Sudar D, Zigon R, Brinkman RR.

Cytometry A. 2010 Jan;77(1):97-100. doi: 10.1002/cyto.a.20825.

11.

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS.

Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.

12.

Data management: it starts at the bench.

Chaussabel D, Ueno H, Banchereau J, Quinn C.

Nat Immunol. 2009 Dec;10(12):1225-7. doi: 10.1038/ni1209-1225. No abstract available.

13.

Publishing flow cytometry data.

Alvarez DF, Helm K, Degregori J, Roederer M, Majka S.

Am J Physiol Lung Cell Mol Physiol. 2010 Feb;298(2):L127-30. doi: 10.1152/ajplung.00313.2009. Epub 2009 Nov 13.

14.

ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring--even in hands of ELISPOT-inexperienced investigators.

Zhang W, Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A, Johannesen K, Vignard V, Dudzik P, Georgakopoulou K, Mihaylova A, Silina K, Aptsiauri N, Adams V, Lehmann PV, McArdle S.

J Immunotoxicol. 2009 Dec;6(4):227-34. doi: 10.3109/15476910903317546.

PMID:
19908941
15.

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA.

Clin Cancer Res. 2009 Nov 15;15(22):7036-44. doi: 10.1158/1078-0432.CCR-09-1544. Epub 2009 Nov 10.

16.

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ.

N Engl J Med. 2009 Nov 5;361(19):1838-47. doi: 10.1056/NEJMoa0810097.

17.

"MIATA"-minimal information about T cell assays.

Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM.

Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.

18.

Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.

Dang Y, Disis ML.

Ann N Y Acad Sci. 2009 Sep;1174:81-7. doi: 10.1111/j.1749-6632.2009.04937.x.

PMID:
19769740
19.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.

20.

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group.

Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z. Epub 2009 Mar 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk